Confirmation of the role of a KRT5 mutation and successful management of skin lesions in a patient with Galli-Galli disease

Clin Exp Dermatol. 2018 Dec;43(8):972-974. doi: 10.1111/ced.13683. Epub 2018 Jun 7.

Authors

K Lőrincz¹, M Medvecz^{1

2}, N Kiss¹, A Glász-Bóna¹, J Hársing¹, R Lepesi-Benkő², Z Hatvani¹, M Mazán¹, S Kárpáti^{1

2}, N Wikonkál¹

Affiliations

¹ Department of Dermatology, Venerology and Dermato-oncology, Semmelweis University, Budapest, Hungary.
² Molecular Medicine Research Group, Hungarian Academy of Sciences, Budapest, Hungary.

PMID: 29882260
DOI: 10.1111/ced.13683

No abstract available

Publication types

Case Reports

MeSH terms

Acantholysis / drug therapy
Acantholysis / genetics*
Acitretin / therapeutic use
Aged
Frameshift Mutation / genetics*
Humans
Keratin-5 / genetics*
Keratolytic Agents / therapeutic use
Male
Recurrence

Substances

KRT5 protein, human
Keratin-5
Keratolytic Agents
Acitretin